Pharmaceutical Investing Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Pharmaceutical Investing Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Pharmaceutical Investing Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Pharmaceutical Investing Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Allied Critical Metals Announces Material Increase to Mineral Resource Estimate at Borralha Tungsten Project in Northern Portugal
